The 7th Academic Conference of CSCO Minimally Invasive Oncology Surgery Committee

Hosted in Shanghai from June 19 to 21, 2026 in hybrid offline-online format, the 7th Academic Conference of the Minimally Invasive Oncology Surgery Committee under Chinese Society of Clinical Oncology (CSCO) serves as a landmark academic platform for domestic and global oncology surgeons. Co-organized by Fudan University Shanghai Cancer Center and multiple professional associations, the event converges top specialists to exchange cutting-edge minimally invasive technologies centered on colorectal tumors, the core research focus of this session.

The conference arranges diversified thematic forums covering robotic-assisted surgery, artificial intelligence-guided precise operation, standardized laparoscopic colorectal procedures, translational research of minimally invasive immunotherapy, and youth surgeon innovation sharing. Renowned domestic and overseas experts deliver keynote speeches on technical upgrades, perioperative quality control, and whole-cycle patient management. It also launches consensus drafting for postoperative complications of rectal cancer surgery, sharing real-world clinical data and live surgical demonstrations to tackle tricky issues in local advanced and recurrent tumor treatment.

First, it unifies technical specifications for minimally invasive oncology surgery across tier-one to grassroots hospitals, narrowing gaps in regional diagnosis and treatment. Second, it bridges clinical practice and medical engineering innovation to accelerate the transformation of advanced surgical devices. Third, it strengthens Sino-foreign academic dialogue, integrating international experience with Chinese patient characteristics to optimize localized therapeutic protocols. Ultimately, the meeting pushes the shift of oncology surgery from radical tumor resection to patient-centered treatment balancing survival benefits and postoperative quality of life, laying a solid foundation for standardized, precise, and humanistic minimally invasive cancer care nationwide.